Navigation Links
Abbott Receives CE Mark Certification

The CE Mark certification has been received by the global healthcare company Abbott towards a new test for detecting the Neissera gonorrhoeae (NG) and Chlamydia trachomatis // (CT) sexually transmitted pathogens. This will enable the company to sell the product in the European Union (EU). The test will be conducted through the Abbott m2000?, which uses real time polymerase chain reaction (PCR) and magnetic particle technology.

Where sexually transmitted diseases are concerned, gonorrhea and chlamydia are the most common, and accurate detection of these diseases can serve to avoid serious illness at a later stage. The European laboratories will be able to get highly reliable test results through the combination of the Abbott m2000 system and the Abbott RealTime? CT/NG assay. The amplified nucleic acid tests can be done on urine samples in a non-invasive manner. Processes like molecular tests, sample preparation and data analysis are automated through the use of the m2000.

As many as 300 million sexually transmitted diseases infections occur across the world annually, according to the World Health Organization (WHO), of which gonorrhea accounts for 55 million and chlamydia accounts for another 85 million. No symptoms are seen in the case of these diseases in 10% of the men and 80% of the women who are infected, even though they are fully capable of infecting others with the disease.

If they are not properly treated, it can result in serious complications like urethritis, sterility, and pelvic inflammatory diseases. Antibiotics are capable of curing both the strains of the disease. Abbott has an alliance with the Celera Diagnostics in Europe through which the test will be made available. Tests are being conducted to detect the hepatitis B virus and HIV/AIDS also through the Abbott m2000 system.
'"/>




Page: 1

Related medicine news :

1. Pharmacia may take 51.5 percent Abbott stake
2. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
3. Abbott’s Laboratories R&D Capabilities Questione
4. Abbott to Subsidize Price of HIV Drug
5. Abbott Offers Aluvia to Thailand in Return for Compulsory Licensing Halt
6. Fifth US Patient Receives Artificial Heart
7. Northfield Labs Receives FDA Comments
8. British MPs Say Prostate Cancer Receives Low Priority in the NHS
9. Zactima Receives Fast Track Designation By The FDA
10. East London Receives World Class New Private Hospital Facility
11. Brinda Karat Receives Legal Notice over Ramdev Issue
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors Luke’s ... June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. ... helping service members that have been wounded in battle and their families. Venture Construction ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that ... dermaka cream can be incorporated into the post-surgical treatment plans of a variety of ... , dermaka cream is very effective for bruising and causes a rapid resolution of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Today, ... optimize the ingestion of their medication by matching users with high quality water pipes ... compare pieces with no commitment. , Inhale was founded by two brothers, Nick and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
Breaking Medicine Technology: